Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Topper EK et al. | Induction of tissue eosinophilia by platelet-activating factor in Merino sheep. | 1992 | Vet. Immunol. Immunopathol. | pmid:1604802 |
Van de Weerdt ML et al. | Ketoprofen and phenylbutazone attenuation of PAF-induced lung inflammation in calves. | 1999 | Vet. J. | pmid:10030127 |
Michelotto PV et al. | Pulmonary inflammation due to exercise-induced pulmonary haemorrhage in Thoroughbred colts during race training. | 2011 | Vet. J. | pmid:22108190 |
da Silva MB et al. | Effect of ketoprofen on PAF-induced bovine platelet aggregation. | 1998 | Vet. J. | pmid:9564275 |
Slauson DO and Sanchez-Vizcaino JM | Leukocyte-dependent platelet vasoactive amine release and immune complex deposition in African swine fever. | 1981 | Vet. Pathol. | pmid:6170156 |
Wimberly HC et al. | Functional and biochemical characterization of immunologically derived equine platelet-activating factor. | 1985 | Vet. Pathol. | pmid:4035942 |
Van de Weerdt ML et al. | Effect of platelet-activating factor on bovine pulmonary function. | 1997 | Vet. Rec. | pmid:9290195 |
Bastos da Silva M et al. | Morphological alterations of blood platelets induced by platelet activating factor (PAF) and partial inhibition by ketoprofen in calves. | 1997 Sep-Oct | Vet. Res. | pmid:9342825 |
Lallès JP et al. | Small intestinal motility disorders in preruminant calves chronically fed a diet based on antigenic soya: characterization and possible mediators. | 1998 Jan-Feb | Vet. Res. | pmid:9559521 |
Bastos da Silva M et al. | In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation. | 2000 Mar-Apr | Vet. Res. | pmid:10779205 |
Diez-Fraile A et al. | Analysis of selective mobilization of L-selectin and Mac-1 reservoirs in bovine neutrophils and eosinophils. | 2003 Jan-Feb | Vet. Res. | pmid:12588684 |
Bastos da Silva MB et al. | The effect of intravenous administration of WEB 2086 on PAF-induced platelet aggregation in healthy Friesian calves. | 1997 | Vet. Res. Commun. | pmid:9345719 |
da Silva MB et al. | Protective effects of WEB 2086 (PAF antagonist) and ketoprofen (NSAID) on PAF-induced changes in the morphological ultrastructure of blood platelets in calves. | 1998 | Vet. Res. Commun. | pmid:9686442 |
Dawson J et al. | Platelet activating factor as a mediator of equine cell locomotion. | 1988 | Vet. Res. Commun. | pmid:3188378 |
Venugopalan CS et al. | Responses of guinea-pig lung parenchymal strips to tracheobronchial lavage fluid from horses affected with summer pasture-associated obstructive pulmonary disease. | 1998 | Vet. Res. Commun. | pmid:9868763 |
DaÄkhin EI et al. | [Clinical significance of studies of platelet activating factor (review of the literature)]. | 1989 Mar-Apr | Vopr. Med. Khim. | pmid:2662595 |
Shebzukhov IuV and Mysiakin EB | [Platelet activating factor--role in regulating the functional activity of the mononuclear phagocyte system]. | 1996 Oct-Dec | Vopr. Med. Khim. | pmid:9254510 |
Muzia GI et al. | [Inhibition of formation of superoxide radicals in leukocytes of hypercholesteremic patients under the effect of a lipid platelet activation factor antagonist]. | 1995 Jul-Aug | Vopr. Med. Khim. | pmid:8571587 |
Denizot Y and Nathan N | Platelet-activating factor in operative salvaged blood. | 1994 | Vox Sang. | pmid:7801619 |
Silliman CC et al. | Stored blood components contain agents that prime the neutrophil NADPH oxidase through the platelet-activating-factor receptor. | 1992 | Vox Sang. | pmid:1332255 |
Sieunarine K et al. | Plasma levels of the lipid mediators, leukotriene B4 and lyso platelet-activating factor, in intraoperative salvaged blood. | 1992 | Vox Sang. | pmid:1333134 |
Robeva R et al. | [Changes in blood coagulation in glomerulonephritis]. | 1982 | Vutr Boles | pmid:6219496 |
Guan Z et al. | [Role of interleukin-6 and platelet-activating factor in delaying neutrophil apoptosis]. | 2000 | Wei Sheng Yan Jiu | pmid:12725051 |
Chmiel B | [The influence of select pathophysiologic factors of acute pancreatitis on erythrocytes' deformability examined in vitro]. | 2002 | Wiad. Lek. | pmid:12715347 |
Keck M et al. | Pathophysiology of burns. | 2009 | Wien Med Wochenschr | pmid:19652939 |
Czarnetzki BM | [Mediators and the bronchial system. Pathophysiologic and biochemical aspects of mediators of the bronchial system]. | 1987 | Wien Med Wochenschr Suppl | pmid:3078398 |
Connolly AB and Vernon DR | Manipulations of the metabolic response for management of patients with severe surgical illness: review. | 2000 | World J Surg | pmid:10773122 |
Bang UC et al. | Pharmacological approach to acute pancreatitis. | 2008 | World J. Gastroenterol. | pmid:18494044 |
Xia SH et al. | Significance of platelet activating factor receptor expression in pancreatic tissues of rats with severe acute pancreatitis and effects of BN52021. | 2007 | World J. Gastroenterol. | pmid:17589953 |
Xia SH et al. | Roles of BN52021 in platelet-activating factor pathway in inflammatory MS1 cells. | 2013 | World J. Gastroenterol. | pmid:23840141 |
Chen Y et al. | Hepatic stellate cells may be potential effectors of platelet activating factor induced portal hypertension. | 2008 | World J. Gastroenterol. | pmid:18186558 |
Lu YY et al. | Synthesis of platelet-activating factor and its receptor expression in Kupffer cells in rat carbon tetrachloride-induced cirrhosis. | 2008 | World J. Gastroenterol. | pmid:18205269 |
Cao HC et al. | Determination of platelet-activating factor by reverse phase high-performance liquid chromatography and its application in viral hepatitis. | 2005 | World J. Gastroenterol. | pmid:16437644 |
Bock J et al. | Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. | 2007 | World J. Gastroenterol. | pmid:17876892 |
Liu LR and Xia SH | Role of platelet-activating factor in the pathogenesis of acute pancreatitis. | 2006 | World J. Gastroenterol. | pmid:16489665 |
Zhou ZG and Chen YD | Influencing factors of pancreatic microcirculatory impairment in acute panceatitis. | 2002 | World J. Gastroenterol. | pmid:12046059 |
Torres MI and Rios A | Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. | 2008 | World J. Gastroenterol. | pmid:18395894 |
Yang YP et al. | Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis. | 2006 | World J. Gastroenterol. | pmid:16521183 |
Mathonnet M et al. | Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma. | 2006 | World J. Gastroenterol. | pmid:16718768 |
Karidis NP et al. | Platelet-activating factor in liver injury: a relational scope. | 2006 | World J. Gastroenterol. | pmid:16773686 |
Zhao H et al. | Influence of platelet activating factor on expression of adhesion molecules in experimental pancreatitis. | 2003 | World J. Gastroenterol. | pmid:12532462 |
Sperling RI | Effects of dietary fish oil on leukocyte leukotriene and PAF generation and on neutrophil chemotaxis. | 1991 | World Rev Nutr Diet | pmid:2053354 |
Tanaka E et al. | Dual effects of a novel thienodiazepine platelet-activating factor antagonist, on drug-oxidizing enzymes in beagle dog. | 1994 | Xenobiotica | pmid:8059533 |
Nunoya K et al. | S-oxidation of (+)-cis-3,5-dimethyl-2-(3-pyridyl)-thiazolidin-4-one hydrochloride by rat hepatic flavin-containing monooxygenase 1 expressed in yeast. | 1995 | Xenobiotica | pmid:8719904 |
Thomson KL et al. | Metabolism of the platelet-activating factor antagonist (+/-)-trans-2-(3'-methoxy-5'-methylsulphonyl-4'-propoxyphenyl)-5-(3",4" ,5"- trimethoxyphenyl)tetrahydrofuran (L-659,989) in rhesus monkeys. | 1991 | Xenobiotica | pmid:1949894 |
Kobayashi T et al. | Metabolism and disposition of (RS)-2-methoxy-3-(octadecylcarbamoyloxy)propyl 2-(3-thiazolio)ethyl phosphate (MOTP) in rats and dogs. | 1988 | Xenobiotica | pmid:3354232 |
Kusano K et al. | Pharmacokinetics of a new thienodiazepine platelet activating factor receptor antagonist (E6123) in laboratory animals. Is there a metabolic polymorphism in the rhesus monkey? | 1993 | Xenobiotica | pmid:8212733 |
Kusano K et al. | Metabolic polymorphism of E6123 in rhesus monkey. | 1993 | Xenobiotica | pmid:8212734 |
Kase N et al. | [Pharmacological profile of F-0401, a novel dihydropyridine derivative. III. The anti-aggregatory action of F-0401 on rabbit platelets]. | 1995 | Yakugaku Zasshi | pmid:7699581 |
Ohishi S | [Evaluation of time course and inter-relationship of inflammatory mediators in experimental inflammatory reaction]. | 2000 | Yakugaku Zasshi | pmid:10825809 |